Second-line treatment for advanced liver cancer after drug resistance
Part of Cancer, Digestive system clinical trials.
This trial tests whether a combination of immunotherapy and targeted therapy can help people with advanced liver cancer whose first treatment stopped working. It aims to shrink tumors and slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer (hepatocellular carcinoma) that cannot be removed with surgery.
- Your cancer has grown after at least 4 cycles of a first-line treatment that combined targeted therapy and immunotherapy.
- You have at least one tumor that can be measured on a scan (at least 10 mm across).
- You are physically active enough to handle daily tasks (ECOG performance status 0 or 1).
- Your liver, kidney, and blood function are within safe limits.
- You have not had any other cancer in the last 5 years and do not have certain other liver cancer types.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of treatments for advanced liver cancer: a targeted therapy (apatinib), an immunotherapy (camrelizumab), and two local treatments (TAE and HAIC). It may be an option if you have a high tumor burden or a tumor thrombus in the portal vein and haven't had systemic treatment before.
This trial tests a combination of radiation therapy, an immunotherapy drug called camrelizumab, and a targeted therapy pill called apatinib for people with advanced liver cancer that has spread to the main blood vessel of the liver. The goal is to see if this triple therapy can shrink tumors and improve outcomes.
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of two medicines (adebrelimab and apatinib) for people with advanced liver cancer who have already tried other treatments. The goal is to see if this combo can slow down the cancer and improve outcomes.
This study tests a combination of liver-directed chemotherapy (given through a small tube into the liver artery), targeted therapy, and an immunotherapy drug (a PD-1 inhibitor) to help prevent liver cancer from coming back after surgery. It is for people whose tumor showed microvascular invasion, which raises the risk of recurrence.
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
Hear when a new Resistance to Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.